4D Molecular Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. 4D Molecular Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 562% to $20,723,000. The net income raised on -$100,837,000 and profit margin reached -487%. Total operating expenses were $133,590,000.
Profit Margin
| 2017 | 5.79M | -11.22M | -193.83% |
|---|---|---|---|
| 2018 | 14.13M | -9.55M | -67.59% |
| 2019 | 6.98M | -52.93M | -757.79% |
| 2020 | 13.61M | -56.54M | -415.38% |
| 2021 | 18.03M | -68.29M | -378.63% |
| 2022 | 3.12M | -101.07M | -3230.3% |
| 2023 | 20.72M | -100.83M | -486.59% |
FDMT Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 20.72M | 3.12M | 18.03M | 13.61M | 6.98M | 14.13M | 5.79M |
Cost of revenue | 97.09M | 3.88M | 3.02M | 53.03M | 38.71M | 0 | 13.57M |
Gross profit | -76.37M | -751K | 15.01M | -39.42M | -31.73M | 14.13M | -7.78M |
Operating exp. | |||||||
Research and development | 97.09M | 80.25M | 61.36M | 53.03M | 38.71M | 18.36M | 13.57M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 133.59M | 113.16M | 89.37M | 70.27M | 52.61M | 24.52M | 17.06M |
Operating income | -112.86M | -110.03M | -71.33M | -56.66M | -50.76M | -10.39M | -11.27M |
Other income (expenses), net | 12.03M | 2.53M | 16K | -29K | 1.45M | -2K | 49K |
Income before tax | -100.83M | -107.49M | -71.31M | -56.69M | -49.30M | -9.55M | -11.22M |
Income tax expense | 0 | -6.41M | -3.02M | -152K | 3.63M | 848K | -89K |
Net income | -100.83M | -101.07M | -68.29M | -56.54M | -52.93M | -9.55M | -11.22M |
Earnings per share | |||||||
Basic EPS | -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
Diluted EPS | -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
| Data source | Data source | Data source | Data source |